Atlas Trials

Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer

Clinical trial NCT06702995 · RECRUITING

Trial details

NCT number
NCT06702995
Sponsor
Evopoint Biosciences Inc.
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Metastatic Castrate-Resistant Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)
Start date
2023-04-19
Primary completion
2026-05-13
Enrollment
307

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.